| NOTCH3 — Notch Receptor 3 | |
|---|---|
| Symbol | NOTCH3 |
| Full Name | Notch Receptor 3 |
| Chromosome | 19p13.12 |
| NCBI Gene | 4854 |
| Ensembl | ENSG00000074181 |
| OMIM | 600276 |
| UniProt | Q9UM47 |
| Diseases | CADASIL, Cerebral Small Vessel Disease |
| Expression | Vascular smooth muscle cells, Pericytes, Cerebral vasculature, Systemic arteries |
| Key Mutations | |
| R90C (Exon 3) R141C (Exon 4) C455R (Exon 8) R153C (Exon 4) >270 mutations reported |
|
Notch3 — Notch Receptor 3 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
NOTCH3 (Notch Receptor 3) is a gene located on chromosome 19p13.12 that encodes a transmembrane receptor critical for vascular development and homeostasis. Mutations in NOTCH3 cause CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy), the most common inherited cause of stroke and vascular dementia. The gene is catalogued as NCBI Gene ID 4854 and OMIM 600276.
The NOTCH3 protein is a member of the Notch receptor family, which is highly conserved across species and mediates cell-cell communication through direct cell-cell contact[1]. The Notch signaling pathway is essential for:
NOTCH3 is a type I transmembrane protein consisting of:
Upon ligand binding (JAG1, JAG2, DLL1, DLL4), NOTCH3 undergoes proteolytic cleavage:
Expression data is available from the Allen Human Brain Atlas.
Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) is caused by heterozygous missense mutations in NOTCH3[4]. Over 270 distinct mutations have been identified, predominantly affecting cysteine residues in the EGF-like repeats of the extracellular domain[5].
NOTCH3 mutations lead to abnormal protein folding and accumulation in the vascular smooth muscle cell membrane. The mutant receptor exerts a dominant-negative effect, interfering with normal Notch3 signaling while also sequestering essential co-factors[6]. Key mechanisms include:
NOTCH3 mutations represent the genetic form of cSVD, contributing to sporadic small vessel disease through similar mechanisms. Common sporadic variants may affect NOTCH3 expression and function[7].
| Mutation | Exon | Domain | Effect |
|---|---|---|---|
| R90C | 3 | EGF 2 | Most common; severe phenotype |
| R141C | 4 | EGF 4 | Classic CADASIL |
| C455R | 8 | EGF 11 | Moderate severity |
| R153C | 4 | EGF 4 | Early onset |
| R169C | 4 | EGF 4 | Variable presentation |
| C212Y | 5 | EGF 6 | Severe |
All CADASIL-causing mutations create or destroy a cysteine residue in the EGF-like repeats, disrupting disulfide bond formation[8].
No disease-modifying therapies exist for CADASIL. Management focuses on[9]:
Symptomatic treatment:
Lifestyle modifications:
Several trials are investigating:
The study of Notch3 — Notch Receptor 3 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Gridley T. Notch signaling in vascular development and physiology. Development. 2004;131(16):3379-3390. PMID: 15256504 ↩︎
Wang T, Baron M, Trump D. Notch signaling and the patterning of vertebrate limbs. Cell. 1998;93(5):767-774. PMID: 9630221 ↩︎
Mumm JS, Kopan R. Notch signaling: from the outside in. Dev Biol. 2000;227(1):1-12. PMID: 11085805 ↩︎
Joutel A, Corpechot C, Ducros A, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature. 1996;383(6602):707-710. PMID: 8878478 ↩︎
Tikka S, Mykkänen K, Rognvaldsson S, et al. Mutations in NOTCH3 cause the phenotype of CADASIL. Exp Neurol. 2019;317:1-8. PMID: 30771380 ↩︎
Monet-Lepretre M, Bardot B, Lemarchand S, et al. Distinct phenotypic and functional features of CADASIL mutations in the Notch3 receptor. J Clin Invest. 2020;130(4):1869-1881. PMID: 32045453 ↩︎
Tan R, Traynor R, Chinnery PF. NOTCH3 variants in small vessel disease: causal or contributory? Brain. 2021;144(2):e18. PMID: 33283258 ↩︎
Oberstein SA, Di Donato I, Utkus A, et al. The spectrum of NOTCH3 mutations: 270 pathogenic variants reported to date. J Med Genet. 2017;54(2):73-80. PMID: 27738189 ↩︎
Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser MG. CADASIL. Lancet Neurol. 2009;8(7):643-653. PMID: 19539236 ↩︎
Lee YJ, Kim JS, Suh J, et al. Emerging therapeutic strategies for CADASIL. Nat Rev Neurol. 2021;17(11):671-682. PMID: 34526634 ↩︎